|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 21, 18973-18978, May 24, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Molecular Medicine Laboratory and Macromolecular
Crystallography Unit, Division of Experimental Medicine, Harvard
Institutes of Medicine, Harvard Medical School, Boston, Massachusetts
02115
Received for publication, February 13, 2002
The Na+/H+
exchanger regulatory factor (NHERF) binds through its PDZ1 domain to
the carboxyl-terminal sequences NDSLL and EDSFL of the The Na+/H+ exchanger regulatory factor
(NHERF)1 is a cytoplasmic
phosphoprotein originally identified as an essential cofactor for the
inhibition of the Na+/H+ exchanger 3 by the
cAMP-dependent protein kinase A in the renal brush-border
membrane (1). NHERF, also known as ezrin/radixin/moesin-binding phosphoprotein 50 or EBP50 (2), contains two PDZ
(PSD-95/Discs-large/ZO-1) domains that bind to carboxyl-terminal
sequences of membrane proteins and an ezrin/radixin/moesin-binding
domain that interacts with the cortical actin cytoskeleton (2, 3).
Through these interactions, NHERF plays central roles in the membrane
targeting, trafficking, and sorting of several ion channels,
transmembrane receptors, and signaling proteins (reviewed in Ref.
4).
Previous studies have shown that the amino-terminal PDZ domain of
NHERF, referred to as PDZ1, binds with high affinity to the carboxyl
termini of the cystic fibrosis transmembrane conductance regulator
(CFTR), PDZ domains are protein-protein interaction modules that participate in
the assembly of membrane receptors, ion channels, and other signaling
molecules into specific signal transduction complexes (11, 12). These
domains bind to short carboxyl-terminal sequence motifs and were
initially grouped into two classes based on target sequence
specificity. Class I domains bind to peptides with the consensus
sequence (S/T)X(V/I/L) (X denoting any amino acid), whereas class II domains recognize the motif
(F/Y)X(F/V/A) (13). However, other PDZ domains have ligand
sequence specificities that do not fall into these two categories,
suggesting the existence of more PDZ classes (11, 12). The PDZ-fold
comprises a six-stranded antiparallel The specificity of the PDZ-ligand interaction is achieved by the
residues at positions Here, we describe the crystal structures of hNHERF PDZ1 bound to the
carboxyl-terminal sequences NDSLL and EDSFL of Protein Purification and Crystallization--
A DNA fragment
encoding the human NHERF PDZ1 domain (residues 11-94) and having the
carboxyl-terminal extension N95DSLL99 that
corresponds to residues 409-413 of human Structure Determination and Refinement--
Both structures were
solved by molecular replacement using the program MOLREP (27) and the
hNHERF PDZ1 (Protein Data Bank code 1g9o) as the search model. For
PDZ1- Overview of the PDZ1-
The hNHERF PDZ1 core domain consists of six Specificity Determinants of the hNHERF PDZ1 Interaction with
As observed previously in the hNHERF PDZ1-CFTR structure (22), in both
PDZ1- Role of the Penultimate Residue in the PDZ-Peptide
Interaction--
As mentioned above, in the hNHERF PDZ1-CFTR
structure, the guanidino group of Arg
Another notable feature in the present structures is that the carbonyl
oxygen atoms of the penultimate residues of both Structural Basis for the PDZ Interaction with Different Penultimate
Residues--
The ability of the hNHERF PDZ1 domain to interact with
different side chains at position Perspective--
This work provides the structural basis for the
interaction of
From a clinical standpoint, because of the central roles of
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The atomic coordinates and the structure factors (code 1gq4 and 1gq5) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).
Published, JBC Papers in Press, March 6, 2002, DOI 10.1074/jbc.M201507200
The abbreviations used are:
NHERF, Na+/H+ exchanger regulatory factor 1;
hNHERF, human NHERF;
Structural Determinants of the Na+/H+
Exchanger Regulatory Factor Interaction with the
2
Adrenergic and Platelet-derived Growth Factor Receptors*
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
2
adrenergic receptor (
2AR) and platelet-derived growth factor receptor, respectively, and plays a critical role in the membrane localization and physiological regulation of these receptors. The crystal structures of the human NHERF PDZ1 domain bound to the
sequences NDSLL and EDSFL have been determined at 1.9- and 2.2-Å
resolution, respectively. The
2AR and platelet-derived growth factor receptor ligands insert into the PDZ1 binding pocket by a
-sheet augmentation process and are stabilized by largely similar
networks of hydrogen bonds and hydrophobic contacts. In the
PDZ1-
2AR complex, the side chain of asparagine at
position
4 in the
2AR peptide forms two additional
hydrogen bonds with Gly30 of PDZ1, which contribute to the
higher affinity of this interaction. Remarkably, both complexes are
further stabilized by hydrophobic interactions involving the side
chains of the penultimate amino acids of the peptide ligands, whereas
the PDZ1 residues Asn22 and Glu43 undergo
conformational changes to accommodate these side chains. These results
provide structural insights into the mechanisms by which different side
chains at the position
1 of peptide ligands interact with PDZ domains
and contribute to the affinity of the PDZ-ligand interaction.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
2 adrenergic receptor (
2AR), and
platelet-derived growth factor receptor (PDGFR) (5-7). The
PDZ1-mediated interaction of NHERF with the carboxyl-terminal motif
DTRL of CFTR is essential for the functional expression in the apical
plasma membrane and gating of the CFTR channel, and the mutations that
destroy this motif result in abnormal apical polarization of CFTR and
defective vectorial chloride transport (8, 9). Likewise, the binding of
the NHERF PDZ1 domain to the
2AR carboxyl-terminal
sequence NDSLL is essential for the
2AR-mediated
regulation of Na+/H+ exchange (6). This
interaction also mediates the sorting of internalized
2AR between degradative endocytic pathways and plasma membrane recycling; the truncation of the
2AR carboxyl
terminus prevents NHERF PDZ1 binding and leads to lysosomal degradation of the receptor (10). Importantly, the phosphorylation of the serine
within the
2AR sequence NDSLL (Ser411 in the
full-length receptor) by the G-protein-coupled receptor kinase-5
inhibits the NHERF PDZ1-
2AR interaction and regulates
2AR endocytic sorting (10). In addition, the NHERF PDZ1
interacts with the motif EDSFL, which is present at the carboxyl
termini of PDGFR forms A and B, and potentiates PDGFR
autophosphorylation and extracellular signal-induced kinase activation
(5, 7). Notably, a single mutation of the PDGFR carboxyl-terminal
leucine to alanine abolishes binding to NHERF PDZ1 and impairs the
receptor activity, demonstrating the critical role of this interaction in PDGFR function (7).
-barrel capped by two
-helices (14-22). Peptide ligands interact with PDZ domains by a
-sheet augmentation process in which the peptide adds an
antiparallel
-strand to the preexisting PDZ
-sheet (23).
3,
2, and 0 of the peptide (position 0 referring to the carboxyl-terminal residue) (11, 12). By contrast,
initial biochemical and structural studies indicated that the residue
at position
1 of the peptide ligand plays no role in the interaction
with PDZ domains (13, 14, 16). However, more recent studies
demonstrated a strong preference of PDZ domains for specific side
chains at position
1, suggesting an important role of these side
chains in the PDZ-ligand interaction (17, 24, 25). In the case of
NHERF, affinity selection experiments showed that PDZ1 selected almost
exclusively ligands with arginine at position
1 from random peptides
(25), and mutagenesis of the penultimate arginine to other residues
decreased the affinity of the PDZ1-ligand interaction (5). A structural
explanation for this preference was provided by the crystal structure
of the human NHERF PDZ1 domain complexed with the CFTR
carboxyl-terminal sequence QDTRL (22). In this structure, the guanidino
group of arginine at position
1 of the CFTR peptide forms two salt bridges and two hydrogen bonds with PDZ1 residues Glu43 and
Asn22, respectively, thus contributing to the affinity of
the PDZ1-ligand interaction. This finding led to the hypothesis that
PDZ residues corresponding to the hNHERF PDZ1 Asn22 and
Glu43 may play a more general role in the interaction with
the penultimate residues of the peptide ligands (22).
2AR and PDGFR, respectively. The structures provide new insights into the
mechanisms by which hydrophobic side chains at position
1 interact
with this domain, contributing to the affinity of the interaction, and
reveal the conformational changes that the PDZ1 residues
Asn22 and Glu43 undergo to accommodate these
side chains.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
2AR was
amplified using the polymerase chain reaction and cloned in the vector
pGEX-2TJL (22). A similar strategy was used to generate the hNHERF PDZ1 domain (residues 11-94) having the carboxyl-terminal extension E95DSFL99 that corresponds to residues
1085-1089 and 1102-1106 of human PDGFRA and PDGFRB,
respectively. The resulting chimeric PDZ1-
2AR and
PDZ1-PDGFR domains were expressed in Escherichia coli BL21 (DE3) cells as glutathione S-transferase fusion proteins
purified using glutathione-Sepharose 4B resin and released from the
glutathione S-transferase moiety by digestion with thrombin
as described previously (21). PDZ1-
2AR protein (19 mg/ml) was crystallized using the sitting drop vapor diffusion method
in 0.1 M citric acid, pH 4.24, and 1 M lithium
chloride at 20 °C, whereas PDZ1-PDGFR (18 mg/ml) was crystallized in
0.1 M sodium acetate, pH 4.6, 2 M sodium
chloride at 20 °C. Both crystals were cryoprotected in 20% (v/v)
glycerol for 3 min and flash-frozen in a stream of liquid nitrogen.
Diffraction data sets were collected at 115 K using CuK
radiation from a Rigaku RU-300 generator and an R-AXIS IV-imaging plate
detector. The data were processed and scaled using the programs DENZO
and SCALEPACK (26) (Table I). Both crystals belong to space group P3121 with one molecule in the asymmetric unit and unit
cell parameters: a = b = 50.37 Å,
c = 66.63 Å (for PDZ1-
2AR) and
a = b = 50.07 Å, c = 66.68 Å (for PDZ1-PDGFR).
2AR, the model was truncated by removing the last
six carboxyl-terminal residues. The rotation function search in the
resolution range from 20.0 to 3.0 Å produced a clear solution with a
peak height of 6.53
above the mean. The translation function
indicated that the correct space group was P3121 with a
correlation coefficient of 47.6% and an R-factor of 47.3%. For the
structure determination of PDZ1-PDGFR, a polyalanine model of hNHERF
PDZ1 was used for molecular replacement in order to remove any model
bias. The rotation function in the resolution range from 20.0 to 3.0 Å produced a solution with a peak height of 6.31
above the mean, and
the translation function indicated that the space group was also
P3121 with a correlation coefficient of 55.6% and an
R-factor of 42.7%. Models were built using the program O (28) and were
refined by the maximum likelihood method using REFMAC5 (29). Both
structures are well ordered with the exception of the loop region
spanning residues 31-35, which is disordered. The crystallized
proteins also contained at their amino termini the vector-derived
residues GSSRM from which only methionine is ordered and included in
both models, whereas arginine is partially ordered and represented as a
glycine in the PDZ1-PDGFR model.
![]()
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
2AR and PDZ1-PDGFR
Structures--
To determine the crystal structures of the hNHERF PDZ1
domain bound to the
2AR and PDGFR
carboxyl-terminal ligands, we adopted a crystallization
strategy similar to that used in the hNHERF PDZ1-CFTR structural
analysis (22). In this approach, we crystallized the hNHERF PDZ1 domain
(residues 11-94) fused to either the
2AR carboxyl-terminal sequence
N95DSLL99 or the PDGFR carboxyl-terminal motif
E95DSFL99 (Fig.
1A). As in the case of hNHERF
PDZ1-CFTR, the hNHERF PDZ1-
2AR and hNHERF PDZ1-PDGFR
crystal structures produced infinite head-to-tail polymers of PDZ1
molecules along the z axis with the carboxyl-terminal pentapeptide extension of one chimeric PDZ1 molecule serving as a
ligand for a neighboring PDZ1 (Fig. 1B). Both crystal
structures were solved by molecular replacement using the hNHERF PDZ1
structure (21) as the search model. The PDZ1-
2AR
structure was refined to an Rcryst of 17.1% and
an Rfree of 18.6%, whereas the PDZ1-PDGFR model
was refined to an Rcryst of 22.2% and an
Rfree of 26.3% (Table
I). An evaluation of the
stereochemistry of the PDZ1-
2AR structure using PROCHECK
(30) showed that 89% of the residues are in the most favored region
and 9.6% in the additional allowed regions. One residue
(Ala81) is disordered and located in the disallowed region
of the Ramachandran plot. A similar analysis of the PDZ1-PDGFR model
placed 87.8% of the residues in the most favored and 12.2% in the
additional allowed regions.

View larger version (42K):
[in a new window]
Fig. 1.
Structure of the hNHERF PDZ1 domain bound to
the
2AR and PDGFR
carboxyl-terminal sequences. A, sequences
of the chimeric hNHERF PDZ1-
2AR (PDZ1B) and
PDZ1-PDGFR (PDZ1P) proteins used in this study. Amino acid
residues belonging to the
2AR and PDGFR carboxyl
termini are shaded in yellow. Secondary structure elements
are indicated at the top. B, stereo view of the hNHERF
PDZ1-
2AR crystal packing. Each carboxyl terminus serves
as a ligand for a neighboring PDZ1 molecule. C, ribbon
diagram of the hNHERF PDZ1 domain bound to the
2AR
carboxyl-terminal sequence NDSLL. A weighted
2Fobs
Fcalc electron
density map calculated at 1.9-Å resolution and contoured at 1.0
is
superimposed on the
2AR ligand. D, ribbon
diagram of the hNHERF PDZ1 domain bound to the PDGFR carboxyl-terminal
sequence EDSFL. A weighted 2Fobs
Fcalc electron density map calculated at 2.2-Å
resolution and contoured at 1.0
is superimposed on the PDGFR ligand.
The figure was made using MOLSCRIPT (35), BOBSCRIPT (36), Raster3D
(37), and POV-Ray (www.povray.org).
Statistics of structure determination and refinement
-strands (
1-
6)
and two
-helices (
1 and
2) (Fig. 1, A,
C, and D). The
2AR and PDGFR
carboxyl-terminal sequences NDSLL and EDSFL, respectively, insert into
the PDZ1 binding pocket as additional
-strands (
7) antiparallel
to
2 and extend the
-sheet of PDZ1. In this arrangement, the
invading pentapeptide ligands are highly ordered as indicated by the
high quality electron density maps (Fig. 1, C and
D) and average B factors of 13.5 Å2 for
2AR and 30.7 Å2 for PDGFR.
2AR and PDGFR--
The stabilization of the
PDZ1-
2AR and PDZ1-PDGFR interactions is achieved through
networks of hydrogen bonds and hydrophobic interactions, which to a
large extent are similar in the two protein-peptide complexes. The side
chains of residues Leu 0, Ser
2, and Asp
3, which are common in
both ligands, are engaged in numerous interactions with PDZ1 residues,
consistent with biochemical evidence on the central role of these
residues in the specificity and affinity of the NHERF PDZ1 interaction
with
2AR and PDGFR (5-10). Specifically, in both
PDZ1-
2AR and PDZ1-PDGFR structures, the side chain and carboxylate group of Leu 0 enter into a deep cavity formed by Tyr24, Gly25, Phe26,
Leu28, Val76, and Ile79 residues.
In this position, the carboxyl oxygen of Leu 0 hydrogen bonds with the
amide nitrogens of Gly25 and Phe26, whereas the
carbonyl oxygen of Leu 0 hydrogen bonds directly with the amide
nitrogen of Tyr24 (Fig. 2,
A-D). The isobutyl group of Leu 0 is stabilized by
hydrophobic interactions with PDZ residues that are largely similar in
both structures (Fig. 2, C and
D). Moreover, in both complexes the amide nitrogen and
carbonyl oxygen atoms of Ser
2 hydrogen bond with the carbonyl oxygen
and amide nitrogen of Leu28, respectively, whereas the
O
1 atom of Ser
2 hydrogen bonds with the
N
2 atom of the conserved His72. These
interactions corroborate previous studies that demonstrated the
critical role of a serine or threonine at position
2 of the ligand
and a histidine at the beginning of the
2 helix for the specificity
of class I PDZ-peptide interactions (5, 6, 10, 12, 13). In the case of
the
2AR ligand, the phosphorylation of Ser
2 by
G-protein-coupled receptor kinase-5 has been shown to abrogate the
interaction with NHERF PDZ1 and play an important role in the
regulation of
2AR endocytic sorting (10). Based on the
current PDZ1-
2AR structure, it could be predicted that the added phosphoryl group on the Ser
2 would sterically clash with
the imidazole group of His72, dislodging the main chain of
the peptide away from the binding pocket and disrupting several
hydrogen bonds that stabilize the PDZ-peptide
-sheet.

View larger version (50K):
[in a new window]
Fig. 2.
PDZ1 interaction with the
2AR and PDGFR carboxyl termini.
A and B, stereo images of the hNHERF PDZ1 binding
pocket bound to the
2AR (A) and PDGFR
(B) carboxyl-terminal ligands. Carbon, oxygen, and nitrogen
atoms are shown in black, red, and
blue, respectively. Water molecules are depicted as
green spheres, and hydrogen bonds are shown as dashed
lines. C and D, two-dimensional representations of
the interactions observed between the hNHERF PDZ1 residues
(orange) and
2AR (C) or PDGFR
(D) peptide ligands (purple). Dashed
lines denote hydrogen bonds, and numbers indicate
hydrogen bond lengths in Å. Hydrophobic interactions are shown as
arcs with radial spokes. C and
D were generated using LIGPLOT (38). E,
superposition of the hNHERF PDZ1 bound to CFTR (yellow),
2AR (blue), and PDGFR (pink)
peptide ligands. For clarity, the
2 strand and
2 helix of the
PDZ1 domain are shown as ribbon diagrams, and only the C
traces are shown for the remaining PDZ1 main chain. Side chains of the
peptide ligands and the PDZ1 residues Asn22 and
Glu43 are shown as ball-and-stick models.
2AR and PDZ1-PDGFR complexes the O
1
atom of Asp
3 hydrogen bonds with N
1 of
His27, the O
2 atom of Asp
3 forms a salt
bridge with N
1 of Arg40, and the carbonyl
oxygen of the residue at position
4 hydrogen bonds with the amide
nitrogen of Gly30 (Fig. 2, A-D). However, in
the PDZ1-
2AR structure the O
1 and
N
2 atoms of Asn
4 make two additional hydrogen bonds
with the amide nitrogen and carbonyl oxygen of Gly30,
respectively (Fig. 2, A and C), that contribute
to the affinity of this interaction.
1 forms two salt bridges with
O
2 of Glu43 and two hydrogen bonds with the
carbonyl oxygen of Asn22 (22). This unexpected finding
suggests that the residue
1 of the peptide plays an important role in
the affinity of the PDZ-ligand interaction. It also raises the question
of whether nonpolar side chains at position
1 of peptide ligands,
such as the large hydrophobic side chains of the penultimate residues of
2AR and PDGFR, interact with the hNHERF PDZ1 or are
disordered facing toward the solution. The present structures clearly
demonstrate that both the isobutyl group of Leu
1 and the phenolic
ring of Phe
1 of the
2AR and PDGFR ligands,
respectively, are well ordered (Fig. 1, C and D)
and engage in hydrophobic interactions with PDZ1 residues.
Specifically, the C
1 atom of the
2AR Leu
1 contacts the C
2 atom of His27, whereas
the C
1 and C
atoms of the PDGFR Phe
1
contact the C
2 and C
1 atoms of
His27, respectively (Fig. 2, A and
B). These results provide compelling structural evidence for
the importance of the penultimate ligand residue in the affinity of the
PDZ-peptide interaction. In agreement with this conclusion, the recent
crystal structure of the InaD PDZ1 complexed with the carboxyl-terminal
sequence of NorpA revealed the presence of an intermolecular disulfide
bond formed between Cys
1 of the peptide ligand and a cysteine
residue of the PDZ domain (31).
2AR and
PDGFR ligands make direct hydrogen bonds with the N
2
atom of Arg80 (Fig. 2, A and B). In
this respect, the PDZ1-
2AR and PDZ1-PDGFR structures
differ from that of PDZ1-CFTR where the carbonyl oxygen of Arg
1 does
not hydrogen bond directly with Arg80 (22). Moreover, the
carbonyl oxygen of Leu 0 interacts indirectly with the N
atom of Arg80 through two ordered water molecules in the
PDZ1-
2AR and PDZ1-CFTR structures but not in the
PDZ1-PDGFR complex. These findings demonstrate that the networks of
hydrogen bonds and ordered water molecules participating in hydrogen
bonding between the PDZ domain and the peptide differ among various
ligands bound to the same PDZ domain.
1 of the peptide ligand raises the question of whether PDZ residues around the binding pocket undergo conformational changes to accommodate different ligands. The
superposition of the hNHERF PDZ1 domains bound to the
2AR, PDGFR, and CFTR peptides reveals the structural
differences among the three complexes and provides insights into the
mechanisms underlying PDZ-ligand recognition. The three liganded hNHERF
PDZ1 structures are very similar with overall root- mean-square
deviations ranging from 0.53 to 0.88 Å (Fig. 2E). Larger
differences in the backbone positions are observed in the
2-
3 and
2-
6 loops with root-mean-square deviation ranges of 1.13-1.98
and 1.08-1.59 Å, respectively. The main chains of the three peptide
ligands and the side chains of residues at positions 0,
2, and
3
are superimposed extremely well, whereas large deviations are observed
in the orientations of the side chains at position
4 (Fig.
2E). To a large extent, the side chains of Phe
1 and Leu
1 follow a path similar to that of the aliphatic portion of the Arg
1 side chain, facing toward the PDZ residues Asn22
and Glu43. Notably, the side chains of these two PDZ
residues exhibit the largest conformational changes seen in all three
complexes. In the PDZ1-
2AR structure, the side chain of
Asn22 is oriented toward the isobutyl group of Leu
1,
whereas in the PDZ1-PDGFR and PDZ1-CFTR complexes, the amide group is
rotated away from the longer side chains of Phe
1 and Arg
1 because of steric effects (Fig. 2E). Remarkably, the
Glu43 side chain occupies three different positions for
optimal ligand interaction. These findings indicate that the
conformational changes of Asn22 and Glu43
underlie the hNHERF PDZ1 flexibility to accommodate ligands with penultimate side chains of different hydrophobicity and polarity and
suggest similar roles for the corresponding residues of other PDZ domains.
2AR and PDGFR with hNHERF PDZ1 and
expands our insights into the molecular mechanisms underlying peptide
recognition by class I PDZ domains. The observed differences in the
hNHERF PDZ1 interaction with the CFTR,
2AR, and PDGFR
ligands also indicate that although PDZ domains are structurally simple
protein interaction modules sharing the same fold, more biochemical and
structural studies are needed to derive the structural principles
governing the selection of their target peptides.
2AR and PDGFR in human physiology and pathology, the
structural determinants of the hNHERF PDZ1 interaction with these
receptors may have important applications in molecular medicine. For
example, this information may be used for the design of a new class of specific inhibitors of these receptors, which would act by disrupting the hNHERF PDZ1-receptor interaction and block the functional localization in plasma membrane and activity of these receptors. It was
previously shown that
2AR agonists induce conformational changes in the receptor that promote a direct physical association of
its carboxyl terminus to the hNHERF PDZ1 (6). Therefore, small
molecules that would block specifically the hNHERF
PDZ1-
2AR interaction could act as
2AR
antagonists. Likewise, the inhibitors of the hNHERF PDZ1-PDGFR
interaction could be useful in reducing the mitogenic activity of this
receptor in tumor cells. In this context, it is of particular interest
to note that the hNHERF gene expression is rapidly activated by
estrogen in estrogen receptor-positive breast cancer cells (32), and
estrogen receptor levels correlate closely with hNHERF expression in
breast carcinomas (33), raising the intriguing possibility that hNHERF
may play an important role in breast cancer development through
potentiation of the PDGFR mitogenic activity (7). Moreover, it was
recently shown that PDGFRA is significantly up-regulated in
metastatic medulloblastoma and enhances the migration properties of
medulloblastoma cells, suggesting that strategies aiming at inhibiting
PDGFRA function could constitute novel therapeutic approaches against
medulloblastoma (34). Therefore, it is conceivable that the hNHERF
PDZ1-PDGFR atomic structure may provide the framework for the design of
small molecules that would block this interaction and decrease the
PDGFR-proliferative activity in cancer cells.
![]()
FOOTNOTES
Established Investigator of the American Heart Association. To
whom correspondence should be addressed: Molecular Medicine Laboratory
and Macromolecular Crystallography Unit, Harvard Institutes of
Medicine, Rm. 354, 4 Blackfan Circle, Boston, MA 02115. Tel.: 617-667-0064; Fax: 617-975-5241; E-mail:
jladias@caregroup.harvard.edu.
![]()
ABBREVIATIONS
2AR,
2 adrenergic receptor;
CFTR, cystic fibrosis transmembrane conductance regulator;
PDZ, PSD-95/Discs-large/ZO-1 homology;
PDGFR, platelet-derived growth factor
receptor.
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
1.
Weinman, E. J.,
Steplock, D.,
Wang, Y.,
and Shenolikar, S.
(1995)
J. Clin. Invest.
95,
2143-2149[Medline]
[Order article via Infotrieve]
2.
Reczek, D.,
Berryman, M.,
and Bretscher, A.
(1997)
J. Cell Biol.
139,
169-179 3.
Murthy, A.,
Gonzalez-Agosti, C.,
Cordero, E.,
Pinney, D.,
Candia, C.,
Solomon, F.,
Gusella, J.,
and Ramesh, V.
(1998)
J. Biol. Chem.
273,
1273-1276 4.
Shenolikar, S.,
and Weinman, E. J.
(2001)
Am. J. Physiol.
280,
F389-F395
5.
Hall, R. A.,
Ostedgaard, L. S.,
Premont, R. T.,
Blitzer, J. T.,
Rahman, N.,
Welsh, M. J.,
and Lefkowitz, R. J.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
8496-8501 6.
Hall, R. A.,
Premont, R. T.,
Chow, C. W.,
Blitzer, J. T.,
Pitcher, J. A.,
Claing, A.,
Stoffel, R. H.,
Barak, L. S.,
Shenolikar, S.,
Weinman, E. J.,
Grinstein, S.,
and Lefkowitz, R. J.
(1998)
Nature
392,
626-630[CrossRef][Medline]
[Order article via Infotrieve]
7.
Maudsley, S.,
Zamah, A. M.,
Rahman, N.,
Blitzer, J. T.,
Luttrell, L. M.,
Lefkowitz, R. J.,
and Hall, R. A.
(2000)
Mol. Cell. Biol.
20,
8352-8363 8.
Moyer, B. D.,
Duhaime, M.,
Shaw, C.,
Denton, J.,
Reynolds, D.,
Karlson, K. H.,
Pfeiffer, J.,
Wang, S.,
Mickle, J. E.,
Milewski, M.,
Cutting, G. R.,
Guggino, W. B., Li, M.,
and Stanton, B. A.
(2000)
J. Biol. Chem.
275,
27069-27074 9.
Raghuram, V.,
Mak, D. D.,
and Foskett, J. K.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
1300-1305 10.
Cao, T. T.,
Deacon, H. W.,
Reczek, D.,
Bretscher, A.,
and von Zastrow, M.
(1999)
Nature
401,
286-290[CrossRef][Medline]
[Order article via Infotrieve]
11.
Hung, A. Y.,
and Sheng, M.
(2002)
J. Biol. Chem.
277,
5699-5702 12.
Harris, B. Z.,
and Lim, W. A.
(2001)
J. Cell Sci.
114,
3219-3231[Medline]
[Order article via Infotrieve]
13.
Songyang, Z.,
Fanning, A. S., Fu, C., Xu, J.,
Marfatia, S. M.,
Chishti, A. H.,
Crompton, A.,
Chan, A. C.,
Anderson, J. M.,
and Cantley, L. C.
(1997)
Science
275,
73-77 14.
Doyle, D. A.,
Lee, A.,
Lewis, J.,
Kim, E.,
Sheng, M.,
and MacKinnon, R.
(1996)
Cell
85,
1067-1076[CrossRef][Medline]
[Order article via Infotrieve]
15.
Morais Cabral, J. H.,
Petosa, C.,
Sutcliffe, M. J.,
Raza, S.,
Byron, O.,
Poy, F.,
Marfatia, S. M.,
Chishti, A. H.,
and Liddington, R. C.
(1996)
Nature
382,
649-652[CrossRef][Medline]
[Order article via Infotrieve]
16.
Daniels, D. L.,
Cohen, A. R.,
Anderson, J. M.,
and Brünger, A. T.
(1998)
Nat. Struct. Biol.
5,
317-325[CrossRef][Medline]
[Order article via Infotrieve]
17.
Schultz, J.,
Hoffmuller, U.,
Krause, G.,
Ashurst, J.,
Macias, M. J.,
Schmieder, P.,
Schneider-Mergener, J.,
and Oschkinat, H.
(1998)
Nat. Struct. Biol.
5,
19-24[CrossRef][Medline]
[Order article via Infotrieve]
18.
Tochio, H.,
Zhang, Q.,
Mandal, P., Li, M.,
and Zhang, M.
(1999)
Nat. Struct. Biol.
6,
417-421[CrossRef][Medline]
[Order article via Infotrieve]
19.
Kozlov, G.,
Gehring, K.,
and Ekiel, I.
(2000)
Biochemistry
39,
2572-2580[CrossRef][Medline]
[Order article via Infotrieve]
20.
Hillier, B. J.,
Christopherson, K. S.,
Prehoda, K. E.,
Bredt, D. S.,
and Lim, W. A.
(1999)
Science
284,
812-815 21.
Karthikeyan, S.,
Leung, T.,
Birrane, G.,
Webster, G.,
and Ladias, J. A. A.
(2001)
J. Mol. Biol.
308,
963-973[CrossRef][Medline]
[Order article via Infotrieve]
22.
Karthikeyan, S.,
Leung, T.,
and Ladias, J. A. A.
(2001)
J. Biol. Chem.
276,
19683-19686 23.
Harrison, S. C.
(1996)
Cell
86,
341-343[CrossRef][Medline]
[Order article via Infotrieve]
24.
Fuh, G.,
Pisabarro, M. T., Li, Y.,
Quan, C.,
Lasky, L. A.,
and Sidhu, S. S.
(2000)
J. Biol. Chem.
275,
21486-21491 25.
Wang, S.,
Raab, R. W.,
Schatz, P. J.,
Guggino, W. B.,
and Li, M.
(1998)
FEBS Lett.
427,
103-108[CrossRef][Medline]
[Order article via Infotrieve]
26.
Otwinowski, Z.,
and Minor, W.
(1997)
Methods Enzymol.
276,
307-326
27.
Vagin, A. A.,
and Teplyakov, A.
(1997)
J. Appl. Crystallogr.
30,
1022-1025[CrossRef]
28.
Jones, T. A.,
Zou, J. Y.,
Cowan, S.,
and Kjeldgaard, M.
(1991)
Acta Crystallogr. Sec. A
47,
110-119[CrossRef]
29.
Murshudov, G. N.,
Vagin, A. A.,
and Dodson, E. J.
(1997)
Acta Crystallogr. Sec. D
53,
240-255[CrossRef][Medline]
[Order article via Infotrieve]
30.
Laskowski, R. J.,
MacArthur, M. W.,
Moss, D. S.,
and Thornton, J. M.
(1993)
J. Appl. Crystallogr.
26,
283-291[CrossRef]
31.
Kimple, M. E.,
Siderovski, D. P.,
and Sondek, J.
(2001)
EMBO J.
20,
4414-4422[CrossRef][Medline]
[Order article via Infotrieve]
32.
Ediger, T. R.,
Kraus, W. L.,
Weinman, E. J.,
and Katzenellenbogen, B. S.
(1999)
Endocrinology
140,
2976-2982 33.
Stemmer-Rachamimov, A. O.,
Wiederhold, T.,
Nielsen, G. P.,
James, M.,
Pinney-Michalowski, D.,
Roy, J. E.,
Cohen, W. A.,
Ramesh, V.,
and Louis, D. N.
(2001)
Am. J. Pathol.
158,
57-62 34.
MacDonald, T. J.,
Brown, K. M.,
LaFleur, B.,
Peterson, K.,
Lawlor, C.,
Chen, Y.,
Packer, R. J.,
Cogen, P.,
and Stephan, D. A.
(2001)
Nat. Genet.
29,
143-152[CrossRef][Medline]
[Order article via Infotrieve]
35.
Kraulis, P. J.
(1991)
J. Appl. Crystallogr.
24,
946-950[CrossRef]
36.
Esnouf, R. M.
(1997)
J. Mol. Graph. Model.
15,
132-134[CrossRef][Medline]
[Order article via Infotrieve]
37.
Merritt, E. A.,
and Murphy, M. E. P.
(1994)
Acta Crystallogr. Sec. D
50,
869-873[CrossRef][Medline]
[Order article via Infotrieve]
38.
Wallace, A. C.,
Laskowski, R. A.,
and Thornton, J. M.
(1995)
Protein Eng.
8,
127-134
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
S. T. Runyon, Y. Zhang, B. A. Appleton, S. L. Sazinsky, P. Wu, B. Pan, C. Wiesmann, N. J. Skelton, and S. S. Sidhu Structural and functional analysis of the PDZ domains of human HtrA1 and HtrA3 Protein Sci., November 1, 2007; 16(11): 2454 - 2471. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Li, P. I. Poulikakos, Z. Dai, J. R. Testa, D. J. E. Callaway, and Z. Bu Protein Kinase C Phosphorylation Disrupts Na+/H+ Exchanger Regulatory Factor 1 Autoinhibition and Promotes Cystic Fibrosis Transmembrane Conductance Regulator Macromolecular Assembly J. Biol. Chem., September 14, 2007; 282(37): 27086 - 27099. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhang, B. A. Appleton, P. Wu, C. Wiesmann, and S. S. Sidhu Structural and functional analysis of the ligand specificity of the HtrA2/Omi PDZ domain Protein Sci., August 1, 2007; 16(8): 1738 - 1750. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Appleton, Y. Zhang, P. Wu, J. P. Yin, W. Hunziker, N. J. Skelton, S. S. Sidhu, and C. Wiesmann Comparative Structural Analysis of the Erbin PDZ Domain and the First PDZ Domain of ZO-1: INSIGHTS INTO DETERMINANTS OF PDZ DOMAIN SPECIFICITY J. Biol. Chem., August 4, 2006; 281(31): 22312 - 22320. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhang, S. Yeh, B. A. Appleton, H. A. Held, P. J. Kausalya, D. C. Y. Phua, W. Lee Wong, L. A. Lasky, C. Wiesmann, W. Hunziker, et al. Convergent and Divergent Ligand Specificity among PDZ Domains of the LAP and Zonula Occludens (ZO) Families J. Biol. Chem., August 4, 2006; 281(31): 22299 - 22311. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Li, Z. Dai, D. Jana, D. J. E. Callaway, and Z. Bu Ezrin Controls the Macromolecular Complexes Formed between an Adapter Protein Na+/H+ Exchanger Regulatory Factor and the Cystic Fibrosis Transmembrane Conductance Regulator J. Biol. Chem., November 11, 2005; 280(45): 37634 - 37643. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Zhou, Y. Xu, Y. Yang, A. Huang, J. Wu, and Y. Shi Solution Structure of AF-6 PDZ Domain and Its Interaction with the C-terminal Peptides from Neurexin and Bcr J. Biol. Chem., April 8, 2005; 280(14): 13841 - 13847. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Shenolikar, J. W. Voltz, R. Cunningham, and E. J. Weinman Regulation of Ion Transport by the NHERF Family of PDZ Proteins Physiology, December 1, 2004; 19(6): 362 - 369. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Hildreth, J.-H. Wu, L. S. Barak, S. T. Exum, L. K. Kim, K. Peppel, and N. J. Freedman Phosphorylation of the Platelet-derived Growth Factor Receptor-{beta} by G Protein-coupled Receptor Kinase-2 Reduces Receptor Signaling and Interaction with the Na+/H+ Exchanger Regulatory Factor J. Biol. Chem., October 1, 2004; 279(40): 41775 - 41782. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Yoo, T. P. Flagg, O. Olsen, V. Raghuram, J. K. Foskett, and P. A. Welling Assembly and Trafficking of a Multiprotein ROMK (Kir 1.1) Channel Complex by PDZ Interactions J. Biol. Chem., February 20, 2004; 279(8): 6863 - 6873. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Raghuram, H. Hormuth, and J. K. Foskett A kinase-regulated mechanism controls CFTR channel gating by disrupting bivalent PDZ domain interactions PNAS, August 5, 2003; 100(16): 9620 - 9625. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. D. Lederer, S. J. Khundmiri, and E. J. Weinman Role of NHERF-1 in Regulation of the Activity of Na-K ATPase and Sodium-Phosphate Co-transport in Epithelial Cells J. Am. Soc. Nephrol., July 1, 2003; 14(7): 1711 - 1719. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Levi Role of PDZ Domain-Containing Proteins and ERM Proteins in Regulation of Renal Function and Dysfunction J. Am. Soc. Nephrol., July 1, 2003; 14(7): 1949 - 1951. [Full Text] [PDF] |
||||
![]() |
A. C. Hamilton, J. Inglese, and M. Ferrer A PDZ domain-based assay for measuring HIV protease activity: Assay design considerations Protein Sci., March 1, 2003; 12(3): 458 - 467. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. J. Skelton, M. F. T. Koehler, K. Zobel, W. L. Wong, S. Yeh, M. T. Pisabarro, J. P. Yin, L. A. Lasky, and S. S. Sidhu Origins of PDZ Domain Ligand Specificity. STRUCTURE DETERMINATION AND MUTAGENESIS OF THE ERBIN PDZ DOMAIN J. Biol. Chem., February 21, 2003; 278(9): 7645 - 7654. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Birrane, J. Chung, and J. A. A. Ladias Novel Mode of Ligand Recognition by the Erbin PDZ Domain J. Biol. Chem., January 10, 2003; 278(3): 1399 - 1402. [Abstract] [Full Text] [PDF] |
||||
| |||